2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 347

Salt Aggravates Arthritis By Th17 Polarization
Abstract Number: 876

SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study
Abstract Number: 1412

Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study
Abstract Number: 735

Sarcopenia in Systemic Sclerosis: Prevalence and Association with Functional Parameters and Quality of Life
Abstract Number: 2862

Satisfaction Following Total Knee Replacement: Journey or Destination?
Abstract Number: 1156

Satisfaction with Rural Rheumatology Telehealth Service
Abstract Number: 1187

Scoring of Spinal Lesions Compatible with Axial Spondyloarthritis on MRI in Clinical Practice By Local Radiologist or Rheumatologist in Desir; Comparison with Central Reading
Abstract Number: 1425

Screening Behavior and Prevalence of Hepatitis C Virus in Mexico
Abstract Number: 2998

Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Abstract Number: 1583

Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp
Abstract Number: 2429

Seasonal Changes May Influence Activity of Rheumatoid Arthritis
Abstract Number: 568

Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years
Abstract Number: L1

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Abstract Number: 953

Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 537

Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].